Biosimilars

Latest News

| Image Credit: NCI/Unsplash
52-Week Data Support MYL-1701P as Aflibercept Biosimilar for DME

September 12th 2024

MYL-1701P showed equivalent efficacy, with comparable safety and immunogenicity, to reference aflibercept in the Phase 3 INSIGHT trial.

Secukinumab Biosimilar Demonstrates Pharmacokinetic Equivalence
Secukinumab Biosimilar Demonstrates Pharmacokinetic Equivalence

September 6th 2024

Biosimilars Month in Review: August 2024
Biosimilars Month in Review: August 2024

September 5th 2024

Bénédicte Caron, Department of Gastroenterology, NFINY Institute and FHU-CURE, Nancy University Hospital, Vandœuvre-lès-Nancy, Inserm, NGERE, University of Lorraine, Nancy, France
Patient Satisfaction High Across Adalimumab Formulations for IBD Treatment

September 3rd 2024

Omalizumab Biosimilar Equivalent to Reference Drug in Children With Severe Allergic Asthma
Omalizumab Biosimilar Equivalent to Reference Drug in Children With Severe Allergic Asthma

August 27th 2024

© 2024 MJH Life Sciences

All rights reserved.